Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Transgene SafiledCriticalSmithkline Beecham Corp
Publication of CR20110461ApublicationCriticalpatent/CR20110461A/en
Investigating Or Analysing Biological Materials
(AREA)
Abstract
La presente invención es en el campo de la inmunoterapia y se refiere a métodos para determinar la eficacia de ciertos tratamientos de inmunoterapia. los métodos de la invención incluyen medir un biomarcador especial en algún momento después de la iniciación del tratamiento de inmunoterapia para evaluar el resultado clínico del citado tratamiento. La invención tiene por consiguiente aplicaciones al campo de la medicina.The present invention is in the field of immunotherapy and refers to methods for determining the efficacy of certain immunotherapy treatments. The methods of the invention include measuring a special biomarker at some time after the initiation of immunotherapy treatment to evaluate the clinical outcome of said treatment. The invention therefore has applications in the field of medicine.
CR20110461A2009-03-242011-08-26
BIOMARCATOR FOR PATIENT MONITORING
CR20110461A
(en)
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation